Bothell, WA, United States of America

Patrick William Gray


Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 32(Granted Patents)


Company Filing History:


Years Active: 1997-1999

Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Inventor Patrick William Gray: Pioneering Advances in TNF.alpha. Technology**

Introduction

Patrick William Gray is a notable inventor based in Bothell, WA, recognized for his contributions to the field of biomedical innovation. With a total of two patents to his name, Gray's work primarily focuses on the development of therapies for diseases mediated by tumor necrosis factor alpha (TNF.alpha.) activity, such as rheumatoid arthritis.

Latest Patents

Gray's latest patents include a groundbreaking invention titled "Nucleic acid encoding modified human TNF.alpha." This innovative DNA molecule encodes a polypeptide capable of binding to human TNF.alpha. The design specifically includes the first three cysteine-rich subdomains of the extracellular binding domain of receptors associated with human TNF.alpha., excluding the fourth subdomain. The significant feature of this polypeptide's ability to bind to TNF.alpha. provides potential for therapeutic applications in treating various TNF.alpha.-mediated diseases.

Career Highlights

Patrick William Gray is currently affiliated with the Mathilda and Terence Kennedy Institute of Rheumatology, where much of his pioneering research is conducted. His expertise in molecular biology and biochemistry has propelled him to the forefront of scientific innovation, particularly concerning autoimmune diseases.

Collaborations

Throughout his career, Gray has collaborated with esteemed colleagues, including Marc Feldmann and Martin John Turner, who are also influential figures in rheumatology research. These partnerships have fostered a collaborative environment that enhances the impact of their work on advancing treatment methodologies for complex diseases.

Conclusion

Inventor Patrick William Gray exemplifies the spirit of innovation in the field of biomedical research. His recent patents not only reflect his dedication to advancing medical science but also offer hope for improved treatment modalities in managing diseases associated with TNF.alpha. activity. As he continues his work at the Mathilda and Terence Kennedy Institute of Rheumatology, the contributions of Gray and his collaborators are sure to influence the future of therapeutic interventions in rheumatology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…